Our Spike Pseudotyped Lentivirus offers a chance to study the mechanism of SARS-CoV-2 viral transduction, as well as screening for neutralizing antibodies and chemical compounds, when used in combination with ACE2 lentivirus. This lentivirus uses SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) instead of VSV-G viral fusion protein as the envelope glycoprotein. Spike mediates the fusion between the viral envelopment and host cell membrane. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.